Nov. 19 at 3:08 PM
$PHIO PHIO’s Other Pipelines:
PH-894:
Preclinical results show it helps the immune system recognize tumors better.
Activates T cells effectively, making it a strong immunotherapy candidate.
PH-804:
Targets TIGIT to boost natural killer cell activity in preclinical models.
Shows promise in enhancing immune response against tumors.
Timeline and Funding:
They’re aiming to move these into clinical trials possibly next year.
Recent warrant funding should support these next steps, giving them a solid cash runway.
